1058 related items for PubMed ID: 17216473
1. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S, Dührsen U, Nückel H.
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[Abstract] [Full Text] [Related]
2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[Abstract] [Full Text] [Related]
3. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.
Nückel H, Dürig J, Dührsen U.
Ann Hematol; 2003 Aug; 82(8):481-486. PubMed ID: 12910375
[Abstract] [Full Text] [Related]
4. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y, Huang ZY, Luo LH, Yu HF.
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[Abstract] [Full Text] [Related]
5. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY, Shi YK, He XH, Zhang P, Dong M, Huang DZ, Yang JL, Zhang CG, Liu P, Yang S, Feng FY.
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[Abstract] [Full Text] [Related]
6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB.
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[Abstract] [Full Text] [Related]
7. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[Abstract] [Full Text] [Related]
8. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[Abstract] [Full Text] [Related]
9. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
Li YH, Jiang WQ, Huang HQ, Zhang L, Liu DG, Xu RH, Zhou ZM, Sun XF, Lin TY, Xu GC, He YJ, Guang ZZ.
Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
[Abstract] [Full Text] [Related]
10. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Salar A, Martino R, Perea G, Ribera JM, López-Guillermo A, Guardia R, Escoda L, Altés A, Sierra J, Montserrat E.
Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
[Abstract] [Full Text] [Related]
11. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.
Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group).
Haematologica; 2008 Dec; 93(12):1829-36. PubMed ID: 18945747
[Abstract] [Full Text] [Related]
12. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J.
Cancer; 2008 Nov 15; 113(10):2734-41. PubMed ID: 18973182
[Abstract] [Full Text] [Related]
13. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG.
Cancer Invest; 2006 Oct 15; 24(6):593-600. PubMed ID: 16982464
[Abstract] [Full Text] [Related]
14. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
Rigacci L, Fabbri A, Puccini B, Chitarrelli I, Chiappella A, Vitolo U, Levis A, Lauria F, Bosi A.
Cancer; 2010 Oct 01; 116(19):4573-9. PubMed ID: 20572029
[Abstract] [Full Text] [Related]
15. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma.
Sym SJ, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, Eom HS, Kim WS, Suh C.
Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):27-33. PubMed ID: 18839172
[Abstract] [Full Text] [Related]
16. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ, Jiang WQ, Wang W, Zhou ZM, Xia ZJ, Lin XB, Li YH, Xu RH, Zhang L, Xu GC, Sun XF, Liu DG, He YJ, Guan ZZ.
Ai Zheng; 2003 Apr 01; 22(4):389-92. PubMed ID: 12703995
[Abstract] [Full Text] [Related]
17. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY, Lin TY, Jiang WQ, Zhang L, Huang HQ, Xia ZJ, Sun XF, He YJ, Guan ZZ.
Ai Zheng; 2004 Dec 01; 23(12):1681-6. PubMed ID: 15601560
[Abstract] [Full Text] [Related]
18. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M, Leonard J, Shuster MW, Kaufman TP.
Eur J Haematol Suppl; 2001 Jul 01; 64():41-5. PubMed ID: 11486401
[Abstract] [Full Text] [Related]
19. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
Biol Blood Marrow Transplant; 2005 Sep 01; 11(9):688-97. PubMed ID: 16125639
[Abstract] [Full Text] [Related]
20. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.
Bone Marrow Transplant; 2002 Dec 01; 30(12):885-91. PubMed ID: 12476281
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
